Supernus Pharmaceuticals, Inc. (SUPN) stock: analyst price target and their real reliability
Live quote · data updated Oct 14, 2026
Supernus Pharmaceuticals, Inc. · Health Care · ref. ETF XLV · 53 calls · price $42.01
What the company does: Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
📈 Supernus Pharmaceuticals, Inc. (SUPN) stock price
$42.01-14.6% over range
Oct 14, 25low $41.28 · high $57Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 1 analysts
📊 JPI status : Supernus Pharmaceuticals, Inc. has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
🎯 SUPN price target & analyst consensus — price $42.01
The price target · all analysts combined (1 targets)
Highest target · 1 firm of 1$67+59.5%
Median target · of 1 targets$67+59.5%
Lowest target · 1 firm of 1$67+59.5%
Current price$42.01
⭐ What the most reliable analysts say
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
The consensus · 1 ratings (last 6 months)
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 SUPN price target all
All 53 calls, one by one, with our verdict on each firm.
→ See all 53 targets, analyst by analyst💡 The best analysts on SUPN most reliable
Their real reliability on SUPN, firm by firm: who was right, who was wrong.
→ See their reliability on SUPNAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Supernus Pharmaceuticals, Inc.? The JPI assistant answers using our backtest data.
🔎 Detailed analyses
✅ Historical analyst reliability on SUPN
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Jefferies ↗ | 86% | +38.2% | 7 |
| Stifel ↗ | 75% | -1.3% | 4 |
| Cantor Fitzgerald ↗ | 67% | +22.0% | 3 |
| Piper Sandler ↗ | 62% | +14.1% | 13 |
| B. Riley Securities ↗ | 50% | -14.0% | 2 |
| Mizuho ↗ | 0% | -37.3% | 2 |
📊 What $1,000 invested in Supernus Pharmaceuticals, Inc. would be worth › open the full page
In short — $1,000 invested in Supernus Pharmaceuticals, Inc. 10 years ago would be worth $3,472 today, i.e. +13%/yr on average. Best year: 2016 (+88%), worst: 2019 (-29%). Price performance, excluding dividends.
If I'd invested $1,000 in Supernus Pharmaceuticals, Inc.
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $1,290 | +29% |
| 3 years ago | $1,308 | +31% |
| 5 years ago | $1,855 | +85% |
Return by year (Supernus Pharmaceuticals, Inc.)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | -6% | $939 (-6%) |
| 2025 | +37% | $1,290 (+29%) |
| 2024 | +25% | $1,612 (+61%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Supernus Pharmaceuticals, Inc.
Loading news…
📋 All analyst calls on SUPN
Filtered on — · ✕ show all
Cantor Fitzgerald ↗
Jul 9, 26
▲ Overweight · 🎯$67
Price at call : $48.46 — upside +38%
Today : $42.01 — upside +59%
🎯 on SUPN : 67% (3 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
in progress (365j)
matures : Jul 9, 27
matures : Jul 9, 27
■ Hold neutral · not a buy · 🎯$55
Price at call : $51.5 — gap to target +7%
Today : $42.01 — gap to target +31%
🎯 on SUPN : 75% (4 calls matureds) · 📊 on Health : 44.3% · +6.0% (97 calls)
in progress (365j)
matures : Dec 19, 26
matures : Dec 19, 26
B of A Securities ↗
Oct 29, 25
▲ Buy · 🎯$65
Price at call : $55.68 — upside +17%
Today : $42.01 — upside +55%
🎯 on SUPN : no call matured yet · 📊 on Health : 51.9% · +3.9% (156 calls)
in progress (365j)
matures : Oct 29, 26
matures : Oct 29, 26
▲ Buy · 🎯$60
Price at call : $52.83 — upside +14%
Today : $42.01 — upside +43%
🎯 on SUPN : no call matured yet · 📊 on Health : 50% · -1.0% (40 calls)
in progress (365j)
matures : Oct 23, 26
matures : Oct 23, 26
Piper Sandler ↗
Oct 9, 25
▲ Overweight · 🎯$65
Price at call : $49.51 — upside +31%
Today : $42.01 — upside +55%
Expected +31% · Actual -14% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 67% (12 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
-13.8%
stock -14% · XLV +18%
matured Oct 9, 26
Cantor Fitzgerald ↗
Sep 30, 25
▲ Overweight · 🎯$63
Price at call : $48.04 — upside +31%
Today : $42.01 — upside +50%
Expected +31% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 67% (3 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
-12.2%
stock -12% · XLV +16%
matured Sep 30, 26
Piper Sandler ↗
Aug 29, 25
■ Neutral neutral · not a buy · 🎯$40
Price at call : $45.12 — gap to target -11%
Today : $42.01 — gap to target -5%
🎯 on SUPN : 67% (12 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
in progress (365j)
matures : Aug 29, 26
matures : Aug 29, 26
Cantor Fitzgerald ↗
Aug 6, 25
▲ Overweight · 🎯$46
Price at call : $41.46 — upside +11%
Today : $42.01 — upside +9%
Expected +11% · Actual +15% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 67% (3 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
+14.9%
stock +15% · XLV +28%
matured Aug 6, 26
See the other 45 calls, newest to oldest
Cantor Fitzgerald ↗
Feb 26, 25
■ Neutral neutral · not a buy · 🎯$36
Price at call : $31.91 — gap to target +13%
Today : $42.01 — gap to target -14%
🎯 on SUPN : 67% (3 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
in progress (365j)
matures : Feb 26, 26
matures : Feb 26, 26
Cantor Fitzgerald ↗
Feb 19, 25
■ Neutral neutral · not a buy · 🎯$36
Price at call : $34.59 — gap to target +4%
Today : $42.01 — gap to target -14%
🎯 on SUPN : 67% (3 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
in progress (365j)
matures : Feb 19, 26
matures : Feb 19, 26
Piper Sandler ↗
Sep 11, 24
■ Neutral neutral · not a buy · 🎯$36
Price at call : $31.08 — gap to target +16%
Today : $42.01 — gap to target -14%
🎯 on SUPN : 67% (12 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
in progress (365j)
matures : Sep 11, 25
matures : Sep 11, 25
Piper Sandler ↗
Feb 28, 24
▲ Overweight · 🎯$41
Price at call : $29.7 — upside +38%
Today : $42.01 — upside -2%
Expected +38% · Actual +8% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 67% (12 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
+8.0%
stock +8% · XLV +3%
matured Feb 27, 25
Piper Sandler ↗
Nov 9, 23
▲ Overweight · 🎯$43
Price at call : $26.65 — upside +61%
Today : $42.01 — upside +2%
Expected +61% · Actual +37% · Reason (≥ +15%) : ✓ Yes
🎯 on SUPN : 67% (12 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
+37.4%
stock +37% · XLV +18%
matured Nov 8, 24
Piper Sandler ↗
Oct 25, 23
▲ Overweight · 🎯$42
Price at call : $22.72 — upside +85%
Today : $42.01 — upside -0%
Expected +85% · Actual +49% · Reason (≥ +15%) : ✓ Yes
🎯 on SUPN : 67% (12 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
+49.3%
stock +49% · XLV +19%
matured Oct 24, 24
Piper Sandler ↗
May 10, 23
▲ Overweight · 🎯$46
Price at call : $35.9 — upside +28%
Today : $42.01 — upside +9%
Expected +28% · Actual -19% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 67% (12 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
-19.3%
stock -19% · XLV +8%
matured May 9, 24
Piper Sandler ↗
Jan 23, 23
▲ Overweight · 🎯$47
Price at call : $41.18 — upside +14%
Today : $42.01 — upside +12%
Expected +14% · Actual -33% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 67% (12 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
-32.7%
stock -33% · XLV +4%
matured Jan 23, 24
Piper Sandler ↗
Aug 31, 22
▲ Overweight · 🎯$38
Price at call : $34.23 — upside +11%
Today : $42.01 — upside -10%
Expected +11% · Actual -7% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 67% (12 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
-7.0%
stock -7% · XLV +7%
matured Aug 31, 23
▲ Buy · 🎯$40
Price at call : $31.29 — upside +28%
Today : $42.01 — upside -5%
Expected +28% · Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 86% (7 calls matureds) · 📊 on Health : 49.6% · +9.4% (137 calls)
+4.3%
stock +4% · XLV +18%
matured Apr 13, 22
Piper Sandler ↗
Jun 16, 20
▲ Overweight · 🎯$31
Price at call : $24.56 — upside +26%
Today : $42.01 — upside -26%
Expected +26% · Actual +35% · Reason (≥ +15%) : ✓ Yes
🎯 on SUPN : 67% (12 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
+35.1%
stock +35% · XLV +24%
matured Jun 16, 21
■ Hold neutral · not a buy · 🎯$24
Price at call : $19.87 — gap to target +21%
Today : $42.01 — gap to target -43%
🎯 on SUPN : 75% (4 calls matureds) · 📊 on Health : 44.3% · +6.0% (97 calls)
in progress (365j)
matures : Apr 16, 21
matures : Apr 16, 21
■ Hold neutral · not a buy · 🎯$23
Price at call : $21.15 — gap to target +9%
Today : $42.01 — gap to target -45%
🎯 on SUPN : 75% (4 calls matureds) · 📊 on Health : 44.3% · +6.0% (97 calls)
in progress (365j)
matures : Nov 6, 20
matures : Nov 6, 20
■ Hold neutral · not a buy
🎯 on SUPN : 86% (7 calls matureds) · 📊 on Health : 49.6% · +9.4% (137 calls)
in progress (365j)
matures : Nov 5, 20
matures : Nov 5, 20
▲ Buy · 🎯$63
Price at call : $35.82 — upside +76%
Today : $42.01 — upside +50%
Expected +76% · Actual -36% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 0% (2 calls matureds) · 📊 on Health : 27.3% · -9.0% (88 calls)
-35.8%
stock -36% · XLV +17%
matured Dec 17, 19
B. Riley Securities ↗
Nov 12, 18
▲ Buy · 🎯$65
Price at call : $45.11 — upside +44%
Today : $42.01 — upside +55%
Expected +44% · Actual -51% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 50% (2 calls matureds) · 📊 on Health : 41.7% · +17.4% (36 calls)
-51.4%
stock -51% · XLV +5%
matured Nov 12, 19
▲ Buy · 🎯$61
Price at call : $46.9 — upside +30%
Today : $42.01 — upside +45%
Expected +30% · Actual -39% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 0% (2 calls matureds) · 📊 on Health : 27.3% · -9.0% (88 calls)
-38.8%
stock -39% · XLV -2%
matured Sep 18, 19
▲ Buy · 🎯$58
Price at call : $46.15 — upside +26%
Today : $42.01 — upside +38%
Expected +26% · Actual -39% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 86% (7 calls matureds) · 📊 on Health : 49.6% · +9.4% (137 calls)
-38.7%
stock -39% · XLV +1%
matured Aug 9, 19
▲ Buy · 🎯$60
Price at call : $57.25 — upside +5%
Today : $42.01 — upside +43%
Expected +5% · Actual -44% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 75% (4 calls matureds) · 📊 on Health : 44.3% · +6.0% (97 calls)
-44.0%
stock -44% · XLV +6%
matured May 25, 19
▲ Buy · 🎯$66
Price at call : $40.7 — upside +62%
Today : $42.01 — upside +57%
Expected +62% · Actual -7% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 0% (1 call matured) · 📊 unranked overall
-7.4%
stock -7% · XLV +3%
matured Feb 1, 19
Janney Montgomery Scott
Dec 4, 17
▲ Buy
Actual +24% · Reason (≥ +15%) : ✓ Yes
🎯 on SUPN : 100% (1 call matured) · 📊 on Health : 61.5% · +15.3% (13 calls)
+23.8%
stock +24% · XLV +13%
matured Dec 4, 18
B. Riley Securities ↗
Nov 8, 17
▲ Buy · 🎯$50
Price at call : $36.9 — upside +36%
Today : $42.01 — upside +19%
Expected +36% · Actual +23% · Reason (≥ +15%) : ✓ Yes
🎯 on SUPN : 50% (2 calls matureds) · 📊 on Health : 41.7% · +17.4% (36 calls)
+23.5%
stock +23% · XLV +14%
matured Nov 8, 18
▲ Buy
Actual +23% · Reason (≥ +15%) : ✓ Yes
🎯 on SUPN : 75% (4 calls matureds) · 📊 on Health : 44.3% · +6.0% (97 calls)
+23.5%
stock +23% · XLV +14%
matured Nov 8, 18
FBR Capital
Oct 19, 17
▲ Buy · 🎯$53
Price at call : $42.6 — upside +24%
Today : $42.01 — upside +26%
Expected +24% · Actual +13% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 100% (1 call matured) · 📊 unranked overall
+13.2%
stock +13% · XLV +9%
matured Oct 19, 18
■ Hold neutral · not a buy
🎯 on SUPN : 75% (4 calls matureds) · 📊 on Health : 44.3% · +6.0% (97 calls)
in progress (365j)
matures : Sep 19, 18
matures : Sep 19, 18
Piper Sandler ↗
Jul 17, 17
■ Neutral neutral · not a buy
🎯 on SUPN : 67% (12 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
in progress (365j)
matures : Jul 17, 18
matures : Jul 17, 18
Janney Montgomery Scott
Jul 14, 17
■ Neutral neutral · not a buy · 🎯$47
Price at call : $44.25 — gap to target +6%
Today : $42.01 — gap to target +12%
🎯 on SUPN : 100% (1 call matured) · 📊 on Health : 61.5% · +15.3% (13 calls)
in progress (365j)
matures : Jul 14, 18
matures : Jul 14, 18
Piper Sandler ↗
Jun 1, 17
▲ Overweight · 🎯$44
Price at call : $38.75 — upside +14%
Today : $42.01 — upside +5%
Expected +14% · Actual +49% · Reason (≥ +15%) : ✓ Yes
🎯 on SUPN : 67% (12 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
+48.9%
stock +49% · XLV +8%
matured Jun 1, 18
Cantor Fitzgerald ↗
Dec 16, 16
▲ Overweight · 🎯$32
Price at call : $23.75 — upside +35%
Today : $42.01 — upside -24%
Expected +35% · Actual +63% · Reason (≥ +15%) : ✓ Yes
🎯 on SUPN : 67% (3 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
+63.4%
stock +63% · XLV +20%
matured Dec 16, 17
▲ Buy · 🎯$28
Price at call : $23.11 — upside +21%
Today : $42.01 — upside -33%
Expected +21% · Actual +82% · Reason (≥ +15%) : ✓ Yes
🎯 on SUPN : 86% (7 calls matureds) · 📊 on Health : 49.6% · +9.4% (137 calls)
+82.2%
stock +82% · XLV +6%
matured Aug 4, 17
Northland Capital Markets ↗
Jul 18, 16
■ Market Perform neutral · not a buy
🎯 on SUPN : 100% (1 call matured) · 📊 on Health : 23.1% · -19.9% (13 calls)
in progress (365j)
matures : Jul 18, 17
matures : Jul 18, 17
Piper Sandler ↗
Jul 18, 16
■ Neutral neutral · not a buy
🎯 on SUPN : 67% (12 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
in progress (365j)
matures : Jul 18, 17
matures : Jul 18, 17
▲ Buy · 🎯$23
Price at call : $17.28 — upside +33%
Today : $42.01 — upside -45%
Expected +33% · Actual +89% · Reason (≥ +15%) : ✓ Yes
🎯 on SUPN : 86% (7 calls matureds) · 📊 on Health : 49.6% · +9.4% (137 calls)
+88.9%
stock +89% · XLV +10%
matured May 12, 17
▲ Buy · 🎯$18
Price at call : $12.54 — upside +44%
Today : $42.01 — upside -57%
Expected +44% · Actual +97% · Reason (≥ +15%) : ✓ Yes
🎯 on SUPN : 86% (7 calls matureds) · 📊 on Health : 49.6% · +9.4% (137 calls)
+96.6%
stock +97% · XLV +13%
matured Feb 7, 17
Northland Capital Markets ↗
Oct 28, 15
▲ Outperform · 🎯$26
Price at call : $16.91 — upside +54%
Today : $42.01 — upside -38%
Expected +54% · Actual +20% · Reason (≥ +15%) : ✓ Yes
🎯 on SUPN : 100% (1 call matured) · 📊 on Health : 23.1% · -19.9% (13 calls)
+20.3%
stock +20% · XLV -3%
matured Oct 27, 16
▲ Buy · 🎯$22
Price at call : $17.09 — upside +29%
Today : $42.01 — upside -48%
Expected +29% · Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 75% (4 calls matureds) · 📊 on Health : 44.3% · +6.0% (97 calls)
+4.3%
stock +4% · XLV -8%
matured Jun 17, 16
Piper Sandler ↗
Jun 18, 15
▲ Overweight · 🎯$20
Price at call : $17.09 — upside +17%
Today : $42.01 — upside -52%
Expected +17% · Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 67% (12 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
+4.3%
stock +4% · XLV -8%
matured Jun 17, 16
▲ Buy · 🎯$18
Price at call : $17.09 — upside +5%
Today : $42.01 — upside -57%
Expected +5% · Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 86% (7 calls matureds) · 📊 on Health : 49.6% · +9.4% (137 calls)
+4.3%
stock +4% · XLV -8%
matured Jun 17, 16
SunTrust Robinson Humphrey
Jun 12, 15
▲ Buy
Actual +3% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 100% (1 call matured) · 📊 unranked overall
+3.3%
stock +3% · XLV -4%
matured Jun 11, 16
■ Hold neutral · not a buy · 🎯$11
Price at call : $11.41 — gap to target -4%
Today : $42.01 — gap to target -74%
🎯 on SUPN : 86% (7 calls matureds) · 📊 on Health : 49.6% · +9.4% (137 calls)
in progress (365j)
matures : Mar 11, 16
matures : Mar 11, 16
■ Hold neutral · not a buy · 🎯$9
Price at call : $8.38 — gap to target +7%
Today : $42.01 — gap to target -79%
🎯 on SUPN : 86% (7 calls matureds) · 📊 on Health : 49.6% · +9.4% (137 calls)
in progress (365j)
matures : Apr 21, 15
matures : Apr 21, 15
▲ Buy · 🎯$14
Price at call : $10.07 — upside +39%
Today : $42.01 — upside -67%
Expected +39% · Actual +11% · Reason (≥ +15%) : ✗ No
🎯 on SUPN : 75% (4 calls matureds) · 📊 on Health : 44.3% · +6.0% (97 calls)
+10.9%
stock +11% · XLV +26%
matured Mar 14, 15
Piper Sandler ↗
May 14, 13
▲ Overweight · 🎯$13
Price at call : $5.48 — upside +137%
Today : $42.01 — upside -69%
Expected +137% · Actual +47% · Reason (≥ +15%) : ✓ Yes
🎯 on SUPN : 67% (12 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
+47.1%
stock +47% · XLV +17%
matured May 14, 14
Piper Sandler ↗
Mar 15, 13
▲ Overweight · 🎯$14
Price at call : $5.54 — upside +153%
Today : $42.01 — upside -67%
Expected +153% · Actual +79% · Reason (≥ +15%) : ✓ Yes
🎯 on SUPN : 67% (12 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
+78.7%
stock +79% · XLV +32%
matured Mar 15, 14
Frequently asked questions
Should I buy Supernus Pharmaceuticals, Inc. stock?
This isn't buy advice. For Supernus Pharmaceuticals, Inc., the analyst consensus is "Buy", with an average price target of $67.00 (+59% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 86% of the time (7 calls tracked on Supernus Pharmaceuticals, Inc.). We show the numbers — you decide.
Is it too late to buy Supernus Pharmaceuticals, Inc.? How high can it go?
The most bullish analyst target on Supernus Pharmaceuticals, Inc. is $67.00 (+59% above today's price); the average is $67.00. That's the upside they see. Check how reliable those analysts have actually been on Supernus Pharmaceuticals, Inc. on our site before trusting it.
Is Supernus Pharmaceuticals, Inc. still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 6 analysts have a real record on Supernus Pharmaceuticals, Inc., the best hitting 86% over 7 calls. Current consensus: "Buy". Make your call on data, not noise.
What has Supernus Pharmaceuticals, Inc.'s past performance been?
Historical returns and a "how much if I had invested" calculator: SUPN performance & returns.
BIIB 
VRTX 
REGN 
UNH 
EW 
SRPT 
VEEV 
BSX